Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Feb 24 th release of 4thQuarter Reduls

<< Previous

Bullboard Posts

Next >>

Comment by longterm56on Feb 10, 2022 8:44am

101 Views

Post# 34415801

RE:RE:RE:RE:Feb 24 th release of 4thQuarter Reduls

So this is the experience of a THTX investor ... we are even disappointed even by the notification that fiscal results will be preleased in two weeks ... that's funny ... but true.

Why am I still here?

-LT

scarlet1967 wrote: I have almost given up on that subject but yes low profile and sub standard communication as usual. The company arranged to meet up with few large shareholders to update only few handpicked investors re their operations what about the rest of the investors? I can go on and on and on.... Folks come to this board for any updates yet many here are also most often are speculating so please THTX....

SPCEO1 wrote: I have a question for the board - is there anything in the release today that caused your heart to skip a beat with anticipation? No, I didn't think so. Maybe that is because they are not yet ready to tell us anything important but maybe it is because they just do not know how to, or simply don't want to, build enthuisiam among investors for their prospects. Supposedly Paul is a marketing expert but he has not yet applied those skills to his interactions with investors. If I were a new potential investor in TH, I don't think I would be inspired to be on that call by the tone of that press release.

palinc2000 wrote: https://stockhouse.com/news/press-releases/2022/02/10/theratechnologies-to-announce-financial-results-for-its-fourth-quarter-and-full